Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.

Date publication

avril 2023

Journal

British journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr BERTAUT Aurélie , Dr LADOIRE Sylvain , Dr DESMOULINS Isabelle , Dr CHARON-BARRA Céline

Tous les auteurs :
Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C, Desmoulins I, Ladoire S, Arnould L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37120672

Résumé

HER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We aimed to estimate them between primary and recurrent tumours, and identify predictive factors.

Référence

Br J Cancer. 2023 04 29;: